Near-term strategies for biotech drug developers facing shifting healthcare dynamics
A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.
Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”
The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024